Skip to content

Deferoxamine to treat Iron Overload in patients on Dialysis: effect on bone, myocardial and liver

Use of Deferoxamine in the treatment of Iron Overload in patients on Dialysis: impact on bone remodeling, myocardial function and liver storage

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3rnskcj
Enrollment
Unknown
Registered
2023-12-11
Start date
2017-02-06
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron

Interventions

This is a prospective non-randomized study in which patients with chronic kidney disease on hemodialysis 3 times a week who had serum ferritin > 1000 ng/ml were invited to participate in this study. T
D02.092.570.394.265

Sponsors

Hospital das Clinicas da Universidade de Sao Paulo
Lead Sponsor
Hospital das Clinicas da Universidade de Sao Paulo
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Adult patient on maintenance hemodialysisl; serum ferritin higher than 1000 ng/ml

Exclusion criteria

Exclusion criteria: Active smoking; Active use of alcohol; Previous use of desferoxamine

Design outcomes

Primary

MeasureTime frame
Found outcome 1: There was a significant decrease in serum iron, transferrin saturation, and ferritin after one year, evaluated through magnetic resonance imaging, although 9 patients (45%) remained with a ferritin level higher than that preconized. Eighteen patients (90%) improved liver accumulation. Regarding the iliac crest, all patients improved and reached normal values. There was no iron accumulation in the heart.;Expected outcome 1: We expected to find a significant (p<0.05) reduction on iron storage in the heart, liver and bones, evaluated by magnetic resonance imaging from baseline to one year

Secondary

MeasureTime frame
Expected outcome 2: We expected to find a change in bone remodelling;Found outcome 2: There was no change in bone remodelling, mineralization or volume.

Countries

Brazil

Contacts

Public ContactVanda Jorgetti

Hospital das Clinicas da Universidade de Sao Paulo

vandajor@usp.br+551126617171

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 5, 2026